ReviewSub-cellular biochemistry2025
New Therapeutic Modalities in Prion Diseases.
Review in Sub-cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prion diseases are fatal neurodegenerative disorders for which no effective therapies exist. Despite decades of drug discovery efforts, progress in developing disease-modifying treatments has been slow. However, recent advances have introduced novel therapeutic modalities targeting key aspects of prion pathology, including prion protein biogenesis, aggregation, and degradation. Advancements in diagnostic tools and highly sensitive prion detection methods are also playing a crucial role in enabling early and accurate diagnosis, which is essential for the timely application of emerging therapeutics. This chapter explores novel therapeutic modalities for prion diseases, focusing on small-molecule theranostics and compounds promoting prion protein degradation, RNA-based therapeutics, and gene therapy approaches. We critically assess the advantages and limitations of these therapeutic strategies, considering their development, efficacy, and translational potential. By leveraging these innovative modalities, the therapeutic toolbox for prion diseases is expanding, offering hope for the development of effective treatments.
Indexed as
Identifiers
41004053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.